Definition
The SURPASS clinical trials comprise a landmark global Phase 3 clinical development program sponsored by Eli Lilly and Company to evaluate the efficacy, safety, and tolerability of tirzepatide—a novel, once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist—in adults with type 2 diabetes mellitus (T2D) (Eli Lilly).
The program consists of several key clinical trials (labeled SURPASS-1 through SURPASS-5, along with regional and long-term extension studies) designed to test tirzepatide both as monotherapy and as an add-on to various background diabetes regimens. The primary endpoint for these trials was the reduction of glycated hemoglobin (HbA1c), with key secondary endpoints focusing on body weight changes, cardiovascular safety, and lipid profile improvements. Across the entire SURPASS program, tirzepatide demonstrated statistically superior and clinically meaningful reductions in HbA1c and body weight compared to placebo and active comparators, including semaglutide, insulin degludec, and insulin glargine (NEJM).
Identities
| Source Type | Identity |
|---|---|
| Wikipedia | Tirzepatide |
| Wikidata | Q99517551 |
| DBpedia | Tirzepatide |
| ProductOntology | N/A |
| Wiktionary | N/A |
| Library of Congress Subject Headings (LCSH) | N/A |
| MeSH | Tirzepatide |
| NCBI Taxonomy | N/A |
| AGROVOC | N/A |
| Google Scholar | SURPASS clinical trials tirzepatide Eli Lilly type 2 diabetes |
| ConceptNet | N/A |
| OpenCyc | N/A |
Also Known As
- SURPASS Clinical Development Program
- Tirzepatide Type 2 Diabetes Trials
- SURPASS Phase 3 Trials
Geography and Climate
The SURPASS clinical trials were conducted across a vast global network of clinical trial sites spanning North America, South America, Europe, Africa, and the Asia-Pacific region. These international sites enrolled thousands of participants from diverse geographic backgrounds, ensuring that the results were globally representative and applicable to different healthcare infrastructures and climates. The regional environmental factors, such as ambient temperature and seasonal changes, are highly relevant to clinical trial logistics, particularly regarding the transport and storage of temperature-sensitive investigational peptides.
Specifically, the SURPASS-AP-Combo trial was a regional study conducted in the Asia-Pacific area, with major enrollment centers in South Korea, Taiwan, and the Philippines. The execution of clinical trials in tropical countries like the Philippines requires strict adherence to cold-chain logistics due to the country’s high relative humidity and ambient temperatures, which regularly exceed 30°C. Investigational products must be shipped and stored in continuous cold storage (2°C to 8°C) from central depots to provincial clinical sites, requiring backup power infrastructure to protect the drug from tropical power grid fluctuations.
Demographics
The demographic profile of participants in the SURPASS program reflected the global epidemiology of type 2 diabetes. The trials enrolled adults (aged 18 and older) with a mean age of approximately 56 to 60 years and an average diabetes duration of 5 to 14 years. The study populations had a balanced distribution of male and female participants, representing diverse racial and ethnic backgrounds including White, Black, Asian, and Hispanic populations.
In the Asia-Pacific cohort, including participants in the Philippines, the clinical trial demographics highlighted unique regional patient characteristics. East and Southeast Asian patients with type 2 diabetes typically present with a lower body mass index (BMI) at diagnosis compared to Western cohorts, yet they exhibit a higher susceptibility to visceral adiposity and early beta-cell dysfunction. The SURPASS trials documented that tirzepatide was highly effective in this demographic, producing significant glycemic improvements even in patients with lower baseline body weights.
Economy and Industry
The economic implications of the SURPASS clinical trials are substantial, shaping the multi-billion dollar global diabetes and weight-management pharmaceutical industry. The positive outcomes of the SURPASS program paved the way for the regulatory approval of tirzepatide under the brand name Mounjaro for type 2 diabetes. This drug has become a major commercial competitor to other incretin-based therapies, particularly Novo Nordisk’s semaglutide.
In the Philippines, the commercialization of tirzepatide represents a major shift in the private healthcare market. As a premium, once-weekly injection, the out-of-pocket cost of tirzepatide is high, making it accessible primarily to middle- and upper-income segments of the population. The high cost of chronic diabetes therapies highlights the economic burden of metabolic diseases in the Philippines, where public health insurance (PhilHealth) coverage for premium biological medications remains limited. The pharmaceutical industry continues to negotiate pricing models and patient-access programs to expand distribution within the domestic market.
Transportation and Infrastructure
The transport and distribution of tirzepatide during and after the SURPASS trials rely on sophisticated cold-chain logistics infrastructure. The drug is a biological peptide formulation that degrades if exposed to freezing temperatures or excessive heat. Logistics providers utilize insulated packaging, temperature-monitoring data loggers, and refrigerated air freight to move the medication from Eli Lilly’s global manufacturing facilities to clinical sites and commercial distributors.
In the Philippines, distribution is managed by specialized pharmaceutical logistics companies that maintain cold-chain warehouses in Metro Manila, Cebu, and Davao. The logistics network utilizes specialized refrigerated vans to transport the product to licensed hospital pharmacies, specialized diabetes clinics, and major retail pharmacy chains. Maintaining the cold chain is critical during the last mile of delivery, especially when shipping to remote island provinces where maritime transport or domestic air cargo may lack dedicated refrigerated storage.
Culture and Tourism
The clinical success of the SURPASS trials, alongside parallel weight-management trials, has sparked a major cultural shift regarding obesity and chronic metabolic diseases. Historically, type 2 diabetes and obesity were culturally stigmatized in the Philippines and other societies as simple failures of willpower or dietary discipline. The clinical validation of dual-receptor agonists has reframed these conditions in public discourse as complex biological diseases driven by endocrine and metabolic dysregulation.
Additionally, the rise of incretin therapies has influenced wellness and medical tourism. High-income patients from neighboring countries travel to medical centers in Manila and other Asian hubs to consult with endocrinologists and access advanced diabetes and weight-management regimens. The cultural influence is also visible in digital spaces, where social media discussions regarding once-weekly injections have generated widespread public interest and shaped lifestyle trends.
Government and Administration
The SURPASS trials provided the foundational clinical evidence required for regulatory filings with government health agencies worldwide, including the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the Philippine Food and Drug Administration. The Philippine FDA reviews trial data to evaluate safety, efficacy, and regional tolerability before granting marketing authorization for the domestic market.
Beyond drug registration, government administration of diabetes therapies involves public health policy and clinical practice guidelines. The Department of Health (DOH) and the Philippine Society of Endocrinology, Diabetes, and Metabolism (PSEDM) integrate evidence from international clinical trials to update national guidelines for managing type 2 diabetes. Government agencies also evaluate whether advanced therapies like tirzepatide should be included in national formularies for public hospitals, balancing clinical efficacy against the economic constraints of the public healthcare budget.
Education and Healthcare
The results of the SURPASS trials are a core component of continuing medical education (CME) for endocrinologists, family physicians, and diabetes educators. Clinical trial data are published in leading medical journals, such as The Lancet and The New England Journal of Medicine, and presented at major international conferences like the American Diabetes Association (ADA) Scientific Sessions.
In clinical practice, healthcare providers use the SURPASS findings to educate patients on the therapeutic benefits of dual GIP/GLP-1 receptor agonists. Endocrinologists explain that tirzepatide targets two distinct gut hormone pathways, helping to stimulate insulin secretion in response to meals, reduce glucagon release, delay gastric emptying, and suppress appetite. Healthcare systems also utilize diabetes nurse educators to train patients on the proper administration of the pre-filled single-dose pen, emphasizing injection technique, dose escalation schedules, and side effect management.
Examples and Analogies
- The Dual-Key Analogy: Imagine a cell receptor as a lock. Older GLP-1 agonists used a single key to unlock the GLP-1 receptor. Tirzepatide behaves like a dual-pronged key that simultaneously unlocks both the GIP and GLP-1 receptors, producing a synergistic effect on insulin secretion and appetite pathways.
- The Thermostat Analogy: In type 2 diabetes, the body’s internal glucose thermostat is broken. Tirzepatide acts as an advanced electronic controller that recalibrates the pancreas and liver, keeping blood glucose levels stable and preventing spikes after meals.
- SURPASS vs. SURMOUNT: The SURPASS program was designed to test tirzepatide in patients with type 2 diabetes, with blood sugar control (HbA1c) as the primary goal. In contrast, the SURMOUNT trials focused on chronic weight management in patients with obesity or overweight, with or without diabetes.
Usage Scenarios
1. Second-Line Diabetes Therapy
A patient with type 2 diabetes who has failed to maintain glycemic control on metformin is prescribed once-weekly tirzepatide based on the SURPASS-2 trial data, aiming to achieve target HbA1c levels (<7.0%) while reducing body weight.
2. High Cardiovascular Risk Management
Following the findings of the SURPASS-4 trial, an endocrinologist prescribes tirzepatide to an older type 2 diabetes patient with established cardiovascular disease, using the drug as an alternative to basal insulin to improve glycemic control without increasing the risk of hypoglycemia.
3. Combination Therapy with Basal Insulin
Based on the SURPASS-5 protocol, a patient who is already using insulin glargine but experiencing persistent daytime hyperglycemia is prescribed tirzepatide as an add-on therapy, allowing for a reduction in the daily insulin dose while improving overall metabolic control.
Strategies
- Gradual Dose Escalation: Start tirzepatide at a low dose (2.5 mg once weekly) for the first 4 weeks, then increase to 5 mg, and continue to escalate by 2.5 mg increments every 4 weeks if needed, up to a maximum dose of 15 mg. This strategy minimizes gastrointestinal side effects.
- Injection Site Rotation: Instruct patients to rotate injection sites weekly between the abdomen, thigh, and upper arm to prevent lipodystrophy and minimize localized injection site reactions.
- Dietary Adjustments: Advise patients to reduce portion sizes and eat slowly, as the delayed gastric emptying caused by the drug can lead to premature fullness and mild nausea if large meals are consumed too quickly.
Security and Safety Measures
- Monitoring for Pancreatitis: Healthcare providers must monitor patients for symptoms of acute pancreatitis, such as persistent, severe abdominal pain radiating to the back. If pancreatitis is suspected, tirzepatide must be discontinued immediately.
- Avoidance in Thyroid Cancer Risk: Due to observations of thyroid C-cell tumors in rodent studies, tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Prevention of Severe Hypoglycemia: When adding tirzepatide to a patient’s existing regimen of insulin or a sulfonylurea, the physician should consider reducing the dose of the insulin secretagogue to lower the risk of hypoglycemia.
Historical Context
The development of incretin-based therapies began in the late 20th century with the discovery of the glucagon-like peptide-1 (GLP-1) hormone and its role in glucose regulation. The first GLP-1 receptor agonist was approved in 2005, followed by once-weekly formulations in the 2010s.
Recognizing that both GIP and GLP-1 play complementary roles in natural glucose metabolism, Eli Lilly initiated the development of tirzepatide as a single molecule capable of binding to both receptors. The Phase 3 SURPASS clinical trial program was launched in 2019 and completed its core trials in 2021. The robust clinical data from these trials led to the landmark US FDA approval of Mounjaro in May 2022, marking the first approved dual GIP/GLP-1 receptor agonist in clinical medicine.
Challenges and Controversies
Gastrointestinal Tolerability
The most frequent challenge observed in the SURPASS trials was gastrointestinal adverse events, including nausea, diarrhea, vomiting, and constipation. While these side effects were typically mild to moderate and occurred primarily during the dose-escalation phase, they led to treatment discontinuation in a small percentage of patients.
Access and Healthcare Equity
The high cost of tirzepatide has raised significant concerns regarding healthcare equity, particularly in developing countries like the Philippines. Critics argue that while the SURPASS trials included diverse global populations, the commercial product remains financially out of reach for the majority of patients with type 2 diabetes in lower-income brackets, highlighting the gap between clinical research and public health accessibility.